Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 01, 2026, titled "New LEQSELVI® (deuruxolitinib) Two-YearData in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026".
Filed with NSE ·
6ix hasn’t read this filing yet.
View original source (NSE India)Company analysis
Earlier from Sun Pharmaceutical Industries
- LIB Therapeutics and Sun Pharma Announce Global Licensing, Commercialization and Manufacturing Agreement for Lerodalcibep, a Novel PCSK9 Inhibitor, Ex-US and China; Lerodalcibep (Lyrokaul®) Approved in the EU
- Sun Pharmaceutical Industries Limited Press Release Sep 28 2026
- Sun Pharma Launches (C)Taro-Methylphenidate ER, the First and Only Bioequivalent to Concerta® with an Osmotic Delivery System
- First-Ever Standardized U.S. Treatment Recommendations Issued for Adults with Severe Alopecia Areata; Sun Pharma Welcomes Milestone